The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway

Oncogene

Volumn 30, Issue 18, 2011, Pages 2098-2107

  Luo, Y ^a,b   Zhou, H ^a   Liu, L ^a   Shen, T ^a   Chen, W ^a   Xu, B ^a   Han, X ^a   Zhang, F ^a   Scott, R S ^a   Alexander, J S ^a   Alam, A ^c   Huang, S ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SICHUAN UNIVERSITY   (China)

^c SANOFI   (France)

Author keywords

ciclopirox; ERK; lymphatic endothelial cells; tube formation; VEGFR 3

Indexed keywords

BETA TUBULIN; CICLOPIROX; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUNGICIDES, INDUSTRIAL; MICE; PYRIDONES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79955633342     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.590     Document Type: Article

References (43)

1. Alitalo K, Carmeliet P. (2002). Molecular mechanisms of lymphan-giogenesis in health and disease. Cancer Cell 1: 219-227. (Pubitemid 41039145)
2. Ando T, Jordan P, Joh T, Wang Y, Jennings MH, Houghton J et al. (2005). Isolation and characterization of a novel mouse lymphatic endothelial cell line: SV-LEC. Lymphat Res Biol 3: 105-115. (Pubitemid 41601246)
3. Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH. (2002). The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 100: 491-498.
4. Cueni LN, Detmar M. (2006). New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol 126: 2167-2177. (Pubitemid 44413162)
5. Dittmar W, Lohaus G. (1973). HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Laboratory results. Arzneimittelforschung 23: 670-674.
6. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K et al. (2003). Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphoryla-tion sites. J Biol Chem 278: 40973-40979. (Pubitemid 37280919)
7. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE et al. (2009). Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114: 3064-3073.
8. Fang C, Miguel MA, Avis I, Martinez A, Zudaire E, Cuttitta F. (2009). Non-peptide small molecule regulators of lymphangiogen-esis. Lymphat Res Biol 7: 189-196.
9. Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP. (1999). Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling. Oncogene 18: 507-514. (Pubitemid 29060626)
10. Fritz-Six KL, Dunworth WP, Li M, Caron KM. (2008). Adrenome-dullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 118: 40-50.
11. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T et al. (2002). Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94: 819-825. (Pubitemid 34705053)
12. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S et al. (2005). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65: 4739-4746. (Pubitemid 40740810)
13. Jin D, Harada K, Ohnishi S, Yamahara K, Kangawa K, Nagaya N. (2008). Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res 80: 339-345.
14. Jue SG, Dawson GW, Brogden RN. (1985). Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs 29: 330-341. (Pubitemid 15092001)
15. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D et al. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92: 3566-3570.
16. Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T et al. (2005). Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev 19: 489-501. (Pubitemid 40256280)
17. Karpanen T, Alitalo K. (2008). Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 3: 367-397. (Pubitemid 351488286)
18. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M et al. (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61: 1786-1790. (Pubitemid 32691984)
19. Karpanen T, Wirzenius M, Makinen T, Veikkola T, Haisma HJ, Achen MG et al. (2006). Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol 169: 708-718. (Pubitemid 44156326)
20. Kerbel RS, Kamen BA. (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436. (Pubitemid 38745528)
21. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B et al. (2005). Inhibition of lymphogenous metastasis using adeno-asso-ciated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65: 6901-6909. (Pubitemid 41060729)
22. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, Wenger RH. (2003). The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB J 17: 761-763.
23. Liu L, Chen L, Chung J, Huang S. (2008). Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 27: 4998-5010.
24. Liu L, Chen L, Luo Y, Chen W, Zhou H, Xu B et al. (2010). Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One 5: e10578.
25. Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S. (2006). Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25: 7029-7040. (Pubitemid 44722071)
26. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ et al. (2001a). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nature Med 7: 199-205. (Pubitemid 32148487)
27. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC et al. (2001b). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20: 4762-4773. (Pubitemid 32848629)
28. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R et al. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682. (Pubitemid 32167632)
29. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K et al. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970. (Pubitemid 24281496)
30. Ming J, Liu N, Gu Y, Qiu X, Wang EH. (2009). PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology 41: 118-126.
31. Nisato RE, Harrison JA, Buser R, Orci L, Rinsch C, Montesano R et al. (2004). Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol 165: 11-24. (Pubitemid 38821810)
32. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. (2003). Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 47: 1805-1817. (Pubitemid 36637799)
33. Pepper MS. (2001). Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 7: 462-468. (Pubitemid 32707965)
34. Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S et al. (2003). CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63: 5978-5991. (Pubitemid 37187500)
35. Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. (2005). Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 106: 3423-3431. (Pubitemid 41609177)
36. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N et al. (2003). T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556. (Pubitemid 36898332)
37. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198. (Pubitemid 32148486)
38. Sigle HC, Thewes S, Niewerth M, Korting HC, Schafer-Korting M, Hube B. (2005). Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. J Antimicrob Chemother 55: 663-673. (Pubitemid 40691844)
39. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al. (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191. (Pubitemid 32148485)
40. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY et al. (2006). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9: 209-223.
41. Sunavala-Dossabhoy G, Fowler M, De Benedetti A. (2004). Translation of the radioresistance kinase TLK1B is induced by gamma-irradiation through activation of mTOR and phosphorylation of 4E-BP1. BMC Mol Biol 5: 1.
42. Wissmann C, Detmar M. (2006). Pathways targeting tumor lymphan-giogenesis. Clin Cancer Res 12: 6865-6868.
43. Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B et al. (2010). The antitumor activity of the fungicide ciclopirox. Int J Cancer 127: 2467-2477.